Raymond James last night initiated coverage of Milestone Pharmaceuticals with a Strong Buy rating and $6 price target. At current share levels, the market is only assigning less than $100M in peak sales for Cardamyst in paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm says this equates to just a 2% penetration into the 2M patient population. Raymond James believes Cardamyst \"has all the fundamentals for a successful launch.\"
